Jump to content

Draft:Salience Health

From Wikipedia, the free encyclopedia
  • Comment: Slow down and read the comments left by reviewers. Please take the time to clean up the promotional tone and add references that meet WP:ORGCRIT to show notability. CNMall41 (talk) 07:03, 5 December 2024 (UTC)

Salience Health

[edit]

Salience Health is a healthcare organization headquartered in Plano, Texas. The company provides integrated care combining psychiatry, primary care, and Transcranial Magnetic Stimulation (TMS) therapy. Its services focus on addressing mental health conditions such as depression, anxiety, and ADHD through a collaborative care model involving healthcare providers with primary care and behavioral health specialties consulting on a course of action for treatment.

Salience Health derives its name from the concept of "salience," which refers to the quality of being particularly noticeable, meaningful, or significant. In the context of healthcare, it symbolizes the organization's focus on prioritizing what matters most for patients—effective treatments, measurable outcomes, and holistic care. In psychiatry and neuroscience, salience refers to the brain's ability to identify and prioritize stimuli that are significant or relevant to a person’s goals, emotions, or environment.

History

[edit]

Salience Health evolved from its parent organization, Salience TMS Neuro Solutions, which specializes in TMS therapy as a treatment for depression. TMS therapy targets and stimulates the Salience Network, an area in the brain that plays a key role in filtering information and directing attention to the most important stimuli, particularly in situations involving decision-making, emotional processing, or stress.

The founders identified a need for greater integration of mental and primary healthcare, leading to the expansion of services to include primary care and testing. This development marked the transition to Salience Health, which adopts a holistic approach by addressing both physical and mental health concerns to treat mood disorders.

The organization operates facilities in the Dallas-Fort Worth area, including locations in Legacy, Plano, McKinney, Allen, Frisco, and Dallas. Salience TMS Neuro Solutions continues to provide TMS therapy, collaboration with external healthcare providers to ensure continuity for patients.

Services

Salience Health offers a services addressing mental health and primary care needs, including:

  • Primary Care Services

Research

[edit]

Salience Health’s approach to mental healthcare is supported by research that highlights the effectiveness of TMS therapy for treating major mood disorders, particularly depression and anxiety. Several studies conducted by Salience and other independent doctors have provided valuable insights into TMS therapy's safety, efficacy, and potential benefits:

  1. Improved Outcomes for Adolescents with Depression Research on TMS therapy for adolescents with major depressive disorder (MDD) found that the treatment is safe and can lead to significant improvements in both depression and anxiety symptoms. This offers a non-invasive alternative for young patients who have not responded to traditional treatments.[1]
  2. Accelerated Relief from Anxiety in Adolescents An accelerated TMS therapy protocol was shown to provide rapid relief for teens with anxiety. Half of the participants showed significant improvement in just 10 days, with reductions in anxiety, depression, and suicidal ideation.[2]
  3. Daily TMS for Adults with Depression A study examining daily TMS treatments for adults with depression found that the therapy significantly improved symptoms compared to a placebo, highlighting its effectiveness for individuals with treatment-resistant depression.[3]
  4. Comprehensive Safety Review of TMS A review of TMS therapy’s safety profile confirmed it as a generally safe treatment option, including for younger populations. While more research is needed, the findings underscore its value as a therapeutic tool for mood and anxiety disorders.[4]
  5. TMS and Anxiety Symptom Relief Combining TMS therapy with medication for generalized anxiety disorder (GAD) was found to be more effective than medication alone, offering a new approach for patients with persistent anxiety symptoms.[5]

These studies explore the efficacy and safety of TMS therapy for various mental health conditions, including depression and anxiety, particularly in adolescent populations.

Research Publication Citations

[edit]
  1. ^ Croarkin, Paul E.; Dojnov, Aleksandra; Middleton, Victoria J.; Bowman, Jennifer; Kriske, Joseph; Donachie, Nancy; Siddiqi, Shan H.; Downar, Jonathan (2024). "Accelerated 1 Hz dorsomedial prefrontal transcranial magnetic stimulation for generalized anxiety disorder in adolescents and young adults: A case series". Brain Stimulation. 17 (2): 269–271. doi:10.1016/j.brs.2024.02.018. PMID 38442801.
  2. ^ Croarkin, Paul E.; Zuckerman, Seth; Middleton, Victoria J.; Monira, Naima; Kriske, Joseph; Bowman, Jennifer; Kriske, John; Donachie, Nancy; Downar, Jonathan (2024). "Clinical outcomes in adolescents undergoing sequential bilateral 1 Hz/20 Hz transcranial magnetic stimulation for treatment resistant depression". Brain Stimulation. 17 (2): 431–433. doi:10.1016/j.brs.2024.03.018. PMID 38570160.
  3. ^ Li, Lucia M.; Violante, Ines R.; Leech, Rob; Hampshire, Adam; Opitz, Alexander; McArthur, David; Carmichael, David W.; Sharp, David J. (2019). "Cognitive enhancement with Salience Network electrical stimulation is influenced by network structural connectivity". NeuroImage. 185: 425–433. doi:10.1016/j.neuroimage.2018.10.069. PMC 6299257. PMID 30385222.
  4. ^ Rossi, Simone; Hallett, Mark; Rossini, Paolo M.; Pascual-Leone, Alvaro (2009). "Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research". Clinical Neurophysiology. 120 (12): 2008–2039. doi:10.1016/j.clinph.2009.08.016. hdl:11572/145680. PMC 3260536. PMID 19833552.
  5. ^ Zhu, Zhaowei; Ding, Yusheng; Wang, Zixi; Cheng, Chuantong; Li, Decai; Chen, Hongda (2020-04-03). "High-performance plasmonic refractive index sensors via synergy between annealed nanoparticles and thin films". Nanotechnology. 31 (25): 255503. Bibcode:2020Nanot..31y5503Z. doi:10.1088/1361-6528/ab7531. ISSN 0957-4484. PMID 32045901.
[edit]